ClinicalTrials.gg
RecruitingNCT07160725Updated Aug 11, 2026

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of BMS-986517 and Pumitamig in Solid Tumours, sponsored by Bristol-Myers Squibb. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

02

Conditions studied

  • Solid Tumours
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have an performance status of 0 to 1.
  • Participants must have by v1.1 (radiologically measured by the Investigator).
  • Participants must have documented or cytologically confirmed advanced, unresectable/ solid tumors, including NSCLC, HNSCC, TNBC, and HR+/- breast cancer.

Exclusion criteria

Exclusion Criteria

  • Participants are eligible if have been treated and do not require immediate treatment or have been treated and have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment).
  • Participants must not have concurrent (present during Screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment.
  • Participants must not have history of serious recurrent infections.
  • Participants must not have impaired cardiac function or history of severe heart disease.
  • For participants in Part 1B and 2B: Active disease or requirement for systemic therapy.
  • For participants in Part 1B and 2B: History of interstitial lung disease (ILD) or pneumonitis requiring systemic , or current/suspected ILD/pneumonitis.
  • For participants in Part 1B and 2B: Significant risk of hemorrhage, including tumor invasion of major vessels or recent bleeding.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Part 1A Monotherapy Dose Escalation

    Drug: BMS-986517

  • Experimental
    Part 1B Combination Dose Escalation

    Drug: BMS-986517 · Drug: Pumitamig

  • Experimental
    Part 1C: Monotherapy PD Sub-study

    Drug: BMS-986517

  • Experimental
    Part 2A: Monotherapy Dose Expansion Cohort A

    Drug: BMS-986517

  • Experimental
    Part 2A: Monotherapy Dose Expansion Cohort B

    Drug: BMS-986517

  • Experimental
    Part 2A: Monotherapy Dose Expansion Cohort C

    Drug: BMS-986517

  • Experimental
    Part 2B: Combination Dose Expansion Cohort A

    Drug: BMS-986517 · Drug: Pumitamig

  • Experimental
    Part 2B: Combination Dose Expansion Cohort B

    Drug: BMS-986517 · Drug: Pumitamig

Interventions

  • DrugBMS-986517

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: BMS-986545, BNT327, PMS002

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AE)

    Time frame: Up to approximately 2 years

  2. Number of Participants with Serious Adverse Events (SAE)

    Time frame: Up to approximately 2 years

  3. Number of Participants with AEs meeting protocol-defined Dose-limiting Toxicities (DLTs) criteria

    For part 1 only

    Time frame: Up to Day 21

  4. Number of Participants with AEs Leading to Discontinuation

    Time frame: Up to approximately 2 years

  5. Number of Participants with AEs Leading to Deaths

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective Response Rate (ORR) Assessed by RECIST v1.1 per investigator assessment

    Time frame: Up to approximately 3 years

  2. Duration of Response (DOR) Assessed by RECIST v1.1 per investigator assessment

    Time frame: Up to approximately 3 years

  3. Maximum Plasma Concentration (Cmax)

    Time frame: Up to approximately 2 years

  4. Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: Up to approximately 2 years

  5. Area Under Curve (AUC)

    Time frame: Up to approximately 2 years

  6. Total anti-drug antibodies (ADAs)

    Time frame: Up to approximately 2 Years

07

Study locations

14 of 20 sites recruiting
  • Local Institution - 0033
    Irvine, California 92612, United States
    Not yet recruiting
    • Site 0033 · Contact
  • USC/Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
    • Anthony El-Khoueiry, Site 0002 · Contact323-865-3967
  • University of California, Irvine (UCI) Health - UC Irvine Medical Center
    Orange, California 92868-3201, United States
    Recruiting
    • Rupali Nabar, Site 0021 · Contact310-222-2222
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Dan Zandberg, Site 0008 · Contact412-864-7955
  • Sanford Cancer Center
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Steven Powell, Site 0005 · Contact605-328-8000
  • START - Dallas Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
    • Henry Xiong, Site 0030 · Contact682-350-3010
  • START San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • START Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
    • William McKean, Site 0031 · Contact801-907-4750
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Lauren Shih, Site 0028 · Contact206-606-7763
  • Local Institution - 0034
    Guangzhou, Guangdong 510120, China
    Not yet recruiting
    • Site 0034 · Contact
  • Herlev and Gentofte Hospital
    Copenhagen, Capital Region 2730, Denmark
    Recruiting
    • Mogens Boisen, Site 0016 · Contact+45 38 68 91 25
  • Odense Universitetshospital
    Odense, Region Syddanmark 5000, Denmark
    Recruiting
    • Annette Kodahl, Site 0015 · Contact+45 21133379
  • Copenhagen University Hospital Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
    • Kristoffer Rohrberg, Site 0017 · Contact+ 45 3545 9540
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
    • Noboru Yamamoto, Site 0029 · Contact81335422511
  • Local Institution - 0026
    Málaga, Andalusia 29010, Spain
    Not yet recruiting
    • Site 0026 · Contact
  • Local Institution - 0022
    Badalona, Barcelona [Barcelona] 08916, Spain
    Not yet recruiting
    • Site 0022 · Contact
  • Local Institution - 0024
    Barcelona, Barcelona [Barcelona] 08035, Spain
    Not yet recruiting
    • Site 0024 · Contact
  • Clinica Universidad de Navarra
    Pamplona, Navarre 31008, Spain
    Recruiting
    • Ignacio Melero Bermejo, Site 0025 · Contact34948255400
  • Hospital Universitario Fundación Jiménez Díaz
    Madrid, 28040, Spain
    Recruiting
    • Victor Moreno Garcia, Site 0027 · Contact915504800ext2805
  • Local Institution - 0023
    Madrid, 28050, Spain
    Not yet recruiting
    • Site 0023 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 8, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Jul 31, 2028
CompletionEst.
Aug 1, 2028
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07160725
Responsible party
Sponsor
First posted
Sep 8, 2025
Start date
Oct 15, 2025
Primary completion
Jul 31, 2028 (estimated)
Completion
Aug 1, 2028 (estimated)
Last update
Aug 11, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion